Puma Biotechnology is a commercial-stage biopharmaceutical company focused on oncology, best known for NERLYNX (neratinib), an oral tyrosine kinase inhibitor for HER2-positive breast cancer. It markets the drug for extended adjuvant treatment and certain metastatic settings, often in combination regimens. The company’s niche is patients and oncologists treating HER2-driven breast cancer after prior anti-HER2 therapy.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 46 | — | 3 | — |
| Q2 2025 | 52.4 | — | 5.9 | — |
| Q3 2025 | 54.5 | — | 8.8 | -59.9% |
| Q4 2025 | 75.5 | — | 13.4 | -36.3% |
| Q1 2026 | 44.8 | -2.6% | -3.8 | -226.2% |
| Q2 2026 | 56.5 | 7.8% | 8.2 | 39.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Editas Medicine, Inc. (EDIT), Teamshares Inc. (TMS), Sight Sciences, Inc. (SGHT), Forward Industries, Inc. (FWDI), Farmers & Merchants Bancorp, Inc. (FMAO), Apex Treasury Corporation (APXT)